The FDA has put on hold three clinical trials involving the immunotherapy pembrolizumab (Keytruda) in combination with other therapies for multiple myeloma, following patient deaths. The US Food and Drug Administration placed two phase III trials on ‘clinical hold’, and a third trial on ‘partial clinical hold’, with the move coming after a data monitoring ...
Keytruda trials on ice after deaths
By Tessa Hoffman
18 Jul 2017